NUVBNuvation Bio Inc.Signing up patients
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
Non-small Cell Lung Cancer (NSCLC)
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 180 (planned)
- Started
- Aug 21, 2025
- Main results expected
- Aug 30, 2030
- Fully finished
- Aug 30, 2033
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Primary Outcome Measure: To compare the efficacy of taletrectinib with that of placebo, as measured by disease-free survival (DFS) by investigator assessment.
Measured over: Time Frame: Up to approximately 5 years after the first patient is randomized (maximum follow-up of 70 months).
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07154706 · record last updated 2026-05-19 · checked 2026-11-09 15:47 UTC